Clinical Trial

KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on…

10 months ago

Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma

Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk…

10 months ago

Cantargia Reports New Preclinical Data on Antitumor Effects of Nadunolimab in Pancreatic Cancer

LUND, SE / ACCESSWIRE / March 5, 2024 / Cantargia (STO:CANTA) (Cantargia AB);(Nasdaq Stockholm: CANTA) today reported new preclinical data…

10 months ago

LinusBio Named “Fierce 15” Company of 2023 by Fierce Medtech

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--LinusBio, a leader in precision exposome sequencing, today announced its inclusion in Fierce Medtech's "Fierce 15" list…

10 months ago

Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

Company Continues to Build and Expand the Global IP Portfolio of Its One-of-a-Kind TechnologyCHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO),…

10 months ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected…

10 months ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum

TORONTO, ON / ACCESSWIRE / March 5, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

10 months ago

Bone Health Technologies Secures $5 Million in Funding to Transform Osteopenia Care

BHT closes oversubscribed financing round, adds new investors to revolutionize low bone density treatmentsREDWOOD CITY, CA / ACCESSWIRE / March…

10 months ago

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans•…

10 months ago

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir’s lead product candidate focused on reversing age-related…

10 months ago